SE Global Equities Corp. Announces Symbol Change and Update
September 20, 2005 03:00 ET
|
Sun New Media Inc.
DIAMOND BAR, Calif., Sept. 20, 2005 (PRIMEZONE) -- SE Global Equities Corp. (OTCBB:SEGB) ("SEG") is pleased to announce that it is in the process of completing the acquisition of Sun New Media Group...
Ahold verkoopt belang in joint venture in Centraal-Amerika
September 20, 2005 02:59 ET
|
Ahold Delhaize
Zaandam, 20 september 2005 - Ahold heeft vandaag bekendgemaakt dat zij overeenstemming heeft bereikt met Wal-Mart Stores Inc. over de verkoop van haar indirecte belang van 33 1/3% in CARHCO N.V....
Crucell Appoints Agents to Boost Asian Market Potential
September 20, 2005 02:06 ET
|
Crucell N.V.
LEIDEN, Netherlands, Sept. 20, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) announced today that it has entered into agreements with Pharma&Soft in...
SEB:s Fondindikator
September 20, 2005 02:00 ET
|
SEB
SEB:s Fondindikator för september visar på ett klart ökat intresse för aktiefonder och ett minskat intresse för räntefonder. I dag kan nästan hälften av alla svenskar tänka sig att investera i en...
Pharming to Present at UBS Global Life Sciences Conference
September 20, 2005 01:38 ET
|
Pharming Group N.V.
LEIDEN, Netherlands, Sept. 20, 2005 (PRIMEZONE) -- Biotech company Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM) (PHARM.AS) announced today that the Company will present at the...
Novartis Presents Positive Phase III Data on Key Compounds and Highlights Strong Late-Stage Development Pipeline
September 20, 2005 01:30 ET
|
Novartis
-- New first-in-class compounds LAF237 (diabetes) and SPP100
(hypertension) set for submission in 2006
-- Robust pipeline with 75 compounds in development, including 52
in Phase II/III...
Novartis stellt positive Phase-III-Daten zu wichtigen Wirkstoffen vor und präsentiert starke Entwicklungspipeline im fortgeschrittenen Stadium
September 20, 2005 01:29 ET
|
Novartis Pharma AG
Erste Vertreter neuer Arzneimittelklassen: Zulassungsanträge für die neuen Wirkstoffe LAF237 (Diabetes) und SPP100 (Bluthochdruck) sind für 2006 geplant
Erfolgversprechende...
Novartis présente des données de phase III positives pour plusieurs molécules clés et dévoile un solide portefeuille de produits en phase avancée de développement
September 20, 2005 01:29 ET
|
Novartis Pharma AG
Les dossiers d'enregistrement de deux nouveaux médicaments, les premiers d'une nouvelle classe thérapeutique : LAF237 (diabète) et SPP100 (hypertension) sont prêts pour 2006
Un...
Novartis presents positive Phase III data on key compounds and highlights strong late-stage development pipeline
September 20, 2005 01:29 ET
|
Novartis Pharma AG
New first-in-class compounds LAF237 (diabetes) and SPP100 (hypertension) set for submission in 2006
Robust pipeline with 75 compounds in development, including 52 in Phase II/III or...
Novartis presents positive Phase III data on key compounds and highlights strong late-stage development pipeline
September 20, 2005 00:28 ET
|
Novartis Pharma AG
New first-in-class compounds LAF237 (diabetes) and SPP100 (hypertension) set for submission in 2006
Robust pipeline with 75 compounds in development, including 52 in Phase II/III or...
- July 26, 2024 17:00 ET Premier American Uranium Outlines Multiple Targets for Expansion Drilling at the Cebolleta Project, New Mexico
- July 26, 2024 16:30 ET Arhaus Unveils Showroom in Palo Alto, California